Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 6.07JFL Life Sciences operates within the Healthcare Services industry, specifically hospitals and diagnostics. The company demonstrates notable strengths in solvency, growth, and coverage ratios. However, it shows weaknesses in liquidity, efficiency, financial metrics, and profitability. While the company exhibits strong growth and can comfortably cover its interest expenses, it struggles with generating profits and managing its short-term obligations. The absence of revenue growth and low financial ratios are areas that need attention. Overall, JFL Life Sciences needs to address its operational inefficiencies and enhance its profitability to ensure long-term sustainability. The company's strong growth and solvency provide a foundation for future improvement, but immediate action is required to tackle its current weaknesses.
Health Score : 6.07JFL Life Sciences operates within the Healthcare Services industry, specifically hospitals and diagnostics. The company demonstrates notable strengths in solvency, growth, and coverage ratios. However, it shows weaknesses in liquidity, efficiency, financial metrics, and profitability. While the company exhibits strong growth and can comfortably cover its interest expenses, it struggles with generating profits and managing its short-term obligations. The absence of revenue growth and low financial ratios are areas that need attention. Overall, JFL Life Sciences needs to address its operational inefficiencies and enhance its profitability to ensure long-term sustainability. The company's strong growth and solvency provide a foundation for future improvement, but immediate action is required to tackle its current weaknesses.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
5.44
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
10.88
P/B RATIO
1.52
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
0.56
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
6.59
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹10.55 as on Sep 1, 2026.
Growth Score : 8.00JFL Life Sciences demonstrates strong growth in several key areas, notably in operating profit, EPS, assets, and net income. These positive trends suggest a company that is expanding effectively. However, the absence of revenue growth is a concern. Addressing the lack of revenue growth while maintaining progress in other areas could lead to even stronger overall performance.
Revenue Growth RatePoorOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 3.03 | 26.47 | 9.3 | 74.47 | 59.76 |
| Operating Profit Growth Rate | 150 | -20 | 25 | 60 | 50 |
| Earnings Per Share (EPS) Growth | -60.67 | -27.12 | 16.28 | 26 | 53.97 |
| Asset Growth Rate | 65.52 | 2.08 | 16.33 | 26.32 | 47.22 |
| Net Income Growth Rate | 200 | 0 | 0 | 33.33 | 50 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Medicamen Organics Ltd | 6.30 | -7.77 | Neutral | -3.75 | -2.50 | -4.02 |
| 2 | Mono Pharmacare Ltd | 6.16 | 42.75 | Neutral | 4.00 | 0.20 | N/A |
| 3 | JFL Life Sciences Ltd | 6.07 | 10.88 | Neutral | 12.00 | 1.94 | 6.00 |
| 4 | Walpar Nutritions Ltd | 5.29 | 9.89 | Neutral | 6.66 | 2.09 | 3.00 |
| 5 | Mangalam Drugs and Organics Ltd | 4.50 | -1.06 | Neutral | -15.00 | -27.68 | -44.00 |
| 6 | Lasa Supergenerics Ltd | 4.39 | -2.61 | Highly Undervalued | -7.00 | -6.80 | -34.00 |
| 7 | Sunrest Lifescience Ltd | 4.17 | 7.60 | Highly Undervalued | 10.21 | 3.60 | 8.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
JFL Life Sciences Ltd. is an Indian pharmaceutical company engaged in the manufacturing and marketing of a diverse range of pharmaceutical formulations. It focuses on various therapeutic areas, serving both domestic and international markets. The company aims to provide affordable and accessible healthcare solutions, leveraging its manufacturing capabilities.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. JFL Life Sciences Ltd's P/E ratio (TTM) is 5.44, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. JFL Life Sciences Ltd's P/B ratio is 1.52, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. JFL Life Sciences Ltd's P/S ratio is 0.56, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. JFL Life Sciences Ltd's PEG ratio is 1.25.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. JFL Life Sciences Ltd's EV/EBITDA ratio is 6.59.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. JFL Life Sciences Ltd's ROE is 13.04%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. JFL Life Sciences Ltd's ROA is 11.32%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. JFL Life Sciences Ltd's ROCE is 18%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. JFL Life Sciences Ltd's operating margin is 9.16%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. JFL Life Sciences Ltd's net margin is 4.58%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. JFL Life Sciences Ltd's current ratio is 1.71.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. JFL Life Sciences Ltd's debt-to-equity ratio is 0.15.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. JFL Life Sciences Ltd's interest coverage ratio is 5.50.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. JFL Life Sciences Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. JFL Life Sciences Ltd's EPS is 53.97.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹10.55. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2004
Headquarters: Ahmedabad, Gujarat
Core Offerings: Injectables, Tablets, Capsules, Liquid Orals, Ointments, Dry Syrups
Stock Listing: NSE (JFLLIFE), BSE ({bse})
Promoter: Hitesh Gandhi / JFL Group
JFL Life Sciences was founded in 2004 as JFL Life Sciences Private Limited, commencing commercial operations in 2005. Over the years, the company expanded its manufacturing capabilities and product portfolio. It converted into a public limited company in 2022 and subsequently listed on the NSE SME platform in February 2023, marking a significant milestone in its corporate journey.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Formulations | 100% | N/A (Integrated segment) |
Pharmaceutical Formulations: Primarily engaged in contract manufacturing of pharmaceutical products for various therapeutic categories, including anti-infectives, anti-inflammatory, gastrointestinal, and dermatology.
Dosage Forms: Specializes in producing a comprehensive range of dosage forms such as tablets, capsules, liquid orals, injections, and ointments, catering to diverse medical needs.
Market Reach: Supplies its products to other pharmaceutical companies, serving both the domestic Indian market and contributing to export opportunities.
Mr. Hitesh Gandhi - Chairman & Managing Director. With over two decades of experience in the pharmaceutical industry, he has been instrumental in establishing and steering the growth of JFL Life Sciences since its inception.
No major subsidiaries reported.
No major recent corporate actions on record, apart from its successful listing on the NSE SME platform in February 2023.
The JFL Life Sciences Ltd share price today is ₹10.55 on NSE (JFLLIFE), as of 26 Sept 2026.
As of 26 Sept 2026, JFL Life Sciences Ltd share price is ₹10.55, with previous close ₹10.55. Today's range is ₹10.55 to ₹10.55. The 52-week range is ₹N/A to ₹N/A.
As of today, JFL Life Sciences Ltd's market cap is ₹72.9 crore (Small Cap).
JFL Life Sciences Ltd's current P/E ratio is 5.44, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 33.
JFL Life Sciences Ltd's current P/B ratio is 1.52.
JFL Life Sciences Ltd's current dividend yield is N/A. Last dividend of ₹0.50 per share was declared on 06-Sep-2024.
JFL Life Sciences Ltd's EPS (TTM) is ₹53.97.
JFL Life Sciences Ltd. is an Indian pharmaceutical company engaged in the manufacturing and marketing of a diverse range of pharmaceutical formulations. It focuses on various therapeutic areas, serving both domestic and international markets. The company aims to provide affordable and accessible healthcare solutions, leveraging its manufacturing capabilities.
JFL Life Sciences Ltd is promoted by Hitesh Gandhi / JFL Group, holding 67.47% as of 26 Sept 2026.
JFL Life Sciences Ltd is listed on NSE (JFLLIFE) and BSE ({bse}). Its next quarterly results are expected on November 2024 (Q2 FY25).
Cash Earnings Per Share (Cash EPS)
